|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Hofstetter, Kerstin; Taugner, Julian 
ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
Käsmann, Lukas; Eze, Chukwuka; Taugner, Julian; Nieto, Alexander; Hofstetter, Kerstin; Kröninger, Sophie; Guggenberger, Julian; Kenndoff, Saskia; Flörsch, Benedikt; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2022):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational new drugs, Bd. 40: S. 163-171
[PDF, 1MB]
Flörsch, Benedikt; Taugner, Julian; Käsmann, Lukas; Kenndoff, Saskia; Guggenberger, Julian; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2022):
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3267-3276
[PDF, 1MB]
Käsmann, Lukas; Taugner, Julian; Eze, Chukwuka; Nieto, Alexander; Pelikan, Carolyn; Flörsch, Benedikt; Kenndoff, Saskia; Hofer, Thomas P.; Nössner, Elfriede; Schulz, Christian; Unterrainer, Marcus; Tufman, Amanda; Klauschen, Frederick; Jung, Andreas; Neumann, Jens; Kumbrink, Jorg; Reinmuth, Niels; Bartenstein, Peter; Belka, Claus und Manapov, Farkhad
(2022):
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
In: Translational Lung Cancer Research, Bd. 11, Nr. 7: S. 1503-1509
[PDF, 294kB]
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational New Drugs, Bd. 40, Nr. 1: S. 163-171